This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

The urine test for bladder cancer will use liquid biopsy technology to diagnose the disease.
6 August 2021
Cancer
University of Birmingham develop urine test for bladder cancer

The University of Birmingham and Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, have partnered to develop a non-invasive test for bladder cancer. The urine test for bladder cancer, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology, and a panel of biomarkers validated by Dr Rik Bryan and Dr Douglas Ward from the University’s Bladder Cancer Research Centre, to diagnose the disease from urine samples.

Bladder cancer is the seventh most common cancer in the developed world. In the UK, over 100,000 people a year are referred to hospital clinics that investigate for bladder cancer, usually after passing blood in their urine (haematuria).  The first stage of investigation is usually cystoscopy, which involves inserting a camera into the bladder. Of these 100,000 patients, around 12% are subsequently diagnosed with bladder cancer, normally after a second invasive procedure to extract a biopsy. 

Dr Bryan, Director of the Bladder Cancer Research Centre,  commented: “While blood visible in the urine should always be investigated, over 80% of people who have a cystoscopy at a haematuria clinic are diagnosed with non-malignant conditions or have no abnormality.  Unfortunately, the remaining 20% will need a further invasive procedure to confirm diagnosis.”

“What is required is a highly sensitive and specific, non-invasive test that can rapidly determine those who need a biopsy and those who do not, and a urine test is the obvious place to start.”

Dr Bryan, Director of the Bladder Cancer Research Centre

While the ‘liquid biopsy’ approach is attractive, the low levels of tumour DNA in a background of DNA from normal tissues requires highly sensitive analytical techniques to obtain accurate results.  However, researchers at the University started their work in the knowledge that Nonacus had pioneered commercial non-invasive prenatal tests to identify low-levels of fetal DNA in maternal blood samples.  Moreover, the company was developing methods to allow confident and sensitive calling of mutations from as little as 10ng of DNA.

The researchers used ‘deep sequencing’ of tumour DNA to identify mutations that are present in the majority of urothelial bladder cancers (UBCs).  Their work, which was funded by Cancer Research UK and an MRC Confidence in Concept grant, involved sequencing 23 genes from tumour samples collected from 956 newly diagnosed, treatment-naïve patients. 

Nonacus intends to launch the new urine test for bladder cancer within 12 months, and the final product will include access to bioinformatics software to help with analysis.  The company expects the test will provide high sensitivity for all stages and grades of disease, and will ensure the test is available worldwide to laboratories, hospitals and clinics. 

Promisingly, the original research also determined the influence of the mutations on cancer progression, time to recurrence, and overall and disease-specific survival in patients with non-muscle-invasive bladder cancer (NMIBC), and disease-specific survival in patients with muscle-invasive bladder cancer (MIBC), raising the possibility that the test could be used to stratify patients according to risk. 

Visit the Bladder Interest Group news page to explore recent industry updates.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...